Cigna on Wednesday said it negotiated with Novo Nordisk and Eli Lilly to secure deeper GLP-1 drug discounts for employers ...

Cigna has announced a deal to cap client copays on popular GLP-1 weight loss drugs by Eli Lilly and Novo Nordisk at $200 per ...

The agreements cap patients’ monthly out-of-pocket costs for Zepbound and Wegovy at $200 and more deeply discount the drugs ...

Cigna subsidiary Evernorth Health Services will automate prior authorizations for GLP-1 weight-loss drugs under a new program ...

Cigna is building on client demand ... announced on Thursday that it had inked a deal with Danish drugmaker Novo Nordisk, which manufactures the GLP-1 Wegovy, to give Wegovy preferred placement ...

Cigna’s Evernorth has reached new deals with manufacturers Eli Lilly and Novo Nordisk to cap patients ... costs at $200 per month and reduces GLP-1 prices for their plan sponsor.

Cigna (NYSE:CI) on Friday announced plans to launch a new specialized GLP-1 pharmacy called ENGUIDE from next month, as the obesity drug class popularized by Novo Nordisk (NVO) and Eli Lilly (NYSE ...

Cigna is building on client demand for tools to support patients on GLP-1 weight loss drugs ... are put off by the medications’ steep list prices and unpredictable long-term outcomes, according ...

where they discuss Novo's GLP-1 weight-loss drug Wegovy, the drugmaker's partnership and price goals with CVS Health (CVS), and the company's outlook on its US manufacturing position and President ...

The price of GLP-1 drugs has attracted the scrutiny of lawmakers, and Novo Nordisk's chief executive Lars Fruergaard Jørgensen has agreed to appear at a Senate hearing next week to defend the ...